BC-11 hydrobromide

Cat. No.:	HY-108447		
CAS No.:	443776-49-6		
Molecular Formula:	C ₈ H ₁₂ BBrN ₂ O ₂ S	NH 	
Molecular Weight:	290.97	H ₂ N S	
Target:	Ser/Thr Protease; SARS-CoV; PAI-1	B-OH	
Pathway:	Metabolic Enzyme/Protease; Anti-infection	H–Br ÓH	
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.		

BIOLOGICAL ACTIVITY		
DIOLOGI		
Descriptio	BC-11 hydrobromide is a selective TMPRSS2 inhibitor (TMPRSS2 is a key host cellular factor for viral entry and SARS-CoV-2 pathogenesis), and a selective urokinase (uPA) inhibitor (IC ₅₀ =8.2 μM). BC-11 hydrobromide is cytotoxic to triple-negative MDA-MB231 breast cancer cells. BC-11 hydrobromide is used in research on viral infections and cancer ^{[1][2][3]} .	
IC₅₀ & Tar	IC50: 8.2 μM (uPA) ^[3] .	

REFERENCES

[1]. Moumbock AFA, et al. BC-11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS-CoV-2 host cell entry. Arch Pharm (Weinheim). 2023 Jan;356(1):e2200371.

[2]. Semina E, et al. Urokinase and urokinase receptor participate in regulation of neuronal migration, axon growth and branching. Eur J Cell Biol. 2016 Sep;95(9):295-310.

[3]. Longo A, et al. Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells. Molecules. 2015 May 28;20(6):9879-89.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Product Data Sheet

